Triple-negative breast cancer has long been one of the most stubborn enemies in oncology. Because its cells lack the estrogen receptor, the progesterone receptor, and HER2, the three molecular handles that guide most breast cancer therapy, patients with this subtype have few options beyond chemotherapy, and resistance develops all too often. Now a team of researchers based in Wuxi, China, has mapped an unexpected internal wiring diagram that helps these tumors thrive, and their findings suggest that two existing drug targets could be attacked at the same time for a stronger blow. Writing in the journal Cancer Immunology, Immunotherapy, the group reports that the immune-regulating molecule B7-H3 does far more than sit on the surface of tumor cells as a passive marker. Instead, it appears to run a signaling program inside the cancer cell itself, sustaining the production of a molecular chaperone that keeps malignant behavior alive.
B7-H3, also known by its scientific name CD276, belongs to the B7 family of immune checkpoint proteins, the same extended family that includes the famous PD-L1 target of modern immunotherapy. In many tumors, B7-H3 is displayed at high levels on the cell surface, where it is thought to help the cancer evade immune surveillance. Earlier clinical work had already shown that patients with triple-negative breast cancer whose tumors carry abundant B7-H3 tend to fare worse, but the question of what the molecule actually does inside these cells remained open. The new study set out to answer that question by combining large public datasets, tissue microarrays from patient samples, multiplex immunofluorescence imaging, RNA sequencing, and a battery of genetic perturbation experiments in the laboratory.
The evidence that B7-H3 matters in this disease is striking. Across the datasets and patient tissue analyses, the team found that B7-H3 was consistently elevated in triple-negative tumors compared with normal breast tissue, and that high expression correlated with poorer overall survival and earlier recurrence. When the researchers forced cancer cells to overproduce B7-H3 in culture, the cells became more aggressive on every measure they tested: they migrated farther, invaded through barriers more effectively, formed more colonies in clonogenic growth assays, and resisted apoptosis, the programmed cell death that would normally cull damaged or abnormal cells. Silencing B7-H3 with small interfering RNAs produced the mirror image of these effects, calming the cells down and restoring their vulnerability to death signals.
To find out how B7-H3 exerts these effects, the team turned to RNA sequencing, a technique that reads out the activity of thousands of genes at once. Comparing cells with high and low B7-H3, one gene stood out from the crowd: HSPA8, which encodes a member of the HSP70 family of heat shock proteins. These chaperones are the cell’s folding assistants, stabilizing newly made proteins and protecting clients from stress-induced damage, and cancer cells often lean on them heavily to survive the hostile conditions inside a tumor. When the researchers depleted HSPA8, the malignant phenotypes that B7-H3 overexpression had created largely collapsed, indicating that this chaperone is a critical downstream effector of B7-H3’s tumor-promoting activity.
The next challenge was to trace the path from a cell-surface protein to a chaperone gene inside the nucleus. The team’s experiments pointed to a two-step relay. First, B7-H3 knockdown reduced the phosphorylation of p38 MAPK, a stress-activated kinase that relays signals from the membrane into the cell. Pharmacological inhibition of p38 MAPK reproduced the same molecular changes, lowering both SP1 and HSPA8. Second, the levels of SP1, a well-known transcription factor that binds gene promoters and switches them on, dropped in parallel. Promoter-reporter assays showed that SP1 drives the transcription of the HSPA8 gene, and when the researchers re-introduced SP1 into cells where B7-H3 had been silenced, HSPA8 expression partially recovered, along with the cells’ ability to form colonies and their resistance to apoptosis.
The authors are careful about how far they push this interpretation. Their data, they note, are consistent with p38 MAPK being involved in the pathway, but the phosphorylation and pharmacological experiments do not establish p38 as an obligatory intermediate in a strictly linear signaling cascade from B7-H3 to HSPA8. This kind of caution matters, because signaling networks in cancer cells are notoriously tangled, and a drug that blocks one kinase often triggers compensatory routes. Still, the chain of evidence, from B7-H3 to p38 phosphorylation to SP1 abundance to HSPA8 transcription, offers a coherent mechanistic account of how a surface immune molecule can shape the internal survival machinery of a tumor cell.
Perhaps the most clinically provocative result came from an experiment that stacked the odds against the cancer. When the researchers added HSPA8 knockdown on top of B7-H3 silencing, the malignant phenotypes were suppressed even further than with B7-H3 knockdown alone, suggesting that the two targets act on partially independent vulnerabilities. Translating that idea into a living animal model, the team tested a combination therapy in syngeneic 4T1 tumors, a mouse breast cancer line that recapitulates key features of the human disease. Mice received an antibody against B7-H3, the HSP70-family inhibitor VER155008, both, or neither. Among the four treatment groups, the combination produced the greatest observed reduction in tumor burden, a result that will surely fuel interest in pairing B7-H3-directed immunotherapy with chaperone blockade.
The implications reach beyond triple-negative breast cancer. B7-H3 is overexpressed in a wide range of malignancies, and several B7-H3-targeting agents, including antibodies, antibody-drug conjugates, and CAR-T cell constructs, are already in clinical development for other cancers. If the intracellular program described here, the p38-SP1-HSPA8 axis, operates in other B7-H3-high tumors as well, it could explain why simply blocking the surface molecule has produced mixed results in some trials, and it offers a rationale for rational combinations that attack both the immune-facing and the survival-facing roles of the protein. HSP70 inhibitors, for their part, have struggled to reach the clinic on their own, partly because chaperones are needed by many normal cells; pairing them with a tumor-selective target like B7-H3 could widen the therapeutic window.
There are, of course, substantial gaps between a mouse experiment and an approved regimen. The combination study used a single syngeneic model, and the authors themselves frame combined targeting of B7-H3 and the HSP70 family as a strategy that warrants further investigation rather than a ready-made therapy. Questions remain about toxicity, dosing, biomarkers for selecting patients, and whether the SP1-dependent regulation of HSPA8 holds in human tumors in real time. The study also relied on RNA interference for much of its genetic work, and validation with additional tools such as CRISPR editing or clinical-grade antibodies will be important. Nevertheless, the work exemplifies a growing trend in cancer biology: treating immune checkpoint molecules not merely as shields against T cells but as signaling hubs whose intracellular functions can be drugged.
For patients with triple-negative breast cancer, the study offers something the field badly needs, a new map of dependencies in a disease defined by the absence of targets. By showing that B7-H3 sustains SP1-dependent HSPA8 expression, and that dismantling this axis weakens the cancer’s migratory, invasive, and survival advantages, the researchers have converted a prognostic marker into a mechanistic hypothesis and, potentially, a combination strategy. The next steps, testing chaperone inhibitors alongside B7-H3 antibodies in larger preclinical models and eventually in carefully designed trials, will determine whether this molecular relay can be turned into a clinical weapon. For now, the message is clear: one of immunology’s favorite surface molecules has a secret life inside the tumor cell, and that secret life may be its greatest weakness.
Subject of Research: The role of B7-H3 in sustaining SP1-dependent HSPA8 expression and driving progression in triple-negative breast cancer
Article Title: B7-H3 promotes triple-negative breast cancer progression by sustaining SP1-dependent HSPA8 expression
Article References: B7-H3 promotes triple-negative breast cancer progression by sustaining SP1-dependent HSPA8 expression. (n.d.). https://doi.org/10.1007/s00262-026-04601-x
Image Credits: AI Generated
DOI: 10.1007/s00262-026-04601-x
Keywords: triple-negative breast cancer, B7-H3, CD276, HSPA8, HSP70, SP1, p38 MAPK, VER155008, immunotherapy, chaperone proteins, cancer signaling, combination therapy
News Source: Nathaniel Bowman. (October 13, 2026). Immune Molecule B7-H3 Drives Triple-Negative Breast Cancer Through a Hidden Protein Machinery. Scienmag.
